Washington University School of Medicine: Carcinoma, Non-Small-Cell Lung trials

The registry lists 30 Carcinoma, Non-Small-Cell Lung studies with Washington University School of Medicine as lead sponsor. 2 are open to participants now and 9 have results posted.

Early Phase 1 1Phase 1 12Phase 2 14No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung CancerRecruitingNCT07355205Phase 1/2
• Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual DiseaseRecruitingNCT06529822Phase 1
• EBUS-Miniforceps Biopsy Specimen Acquisition for PD-L1 Testing in Nonsmall Cell Lung CancerCompletedNCT04159025Not applicableResults posted
• Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung CancerCompletedNCT03916419Phase 2Results posted
• Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLCCompletedNCT03689855Phase 2Results posted
• MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived TumorsTerminatedNCT02669914Phase 2Results posted
• Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung CancerCompletedNCT02299141Phase 2Results posted
• Pazopanib in Molecularly Selected Patients With Advanced NSCLCTerminatedNCT02193152Phase 2Results posted
• Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung CancerTerminatedNCT00921310Phase 1/2Results posted
• A Phase I/II Trial of Stereotactic Body Radiation TherapyCompletedNCT00591838Phase 1/2Results posted
• A Phase II Study of Radiation Therapy, Paclitaxel Poliglumex, and Carboplatin in Stage III Non-Small Cell Lung CancerTerminatedNCT00352690Phase 2Results posted
• Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR) for the Treatment of Central and Ultra-Central Early-Stage Non-Small Cell Lung CancerCompletedNCT05785845Not applicable
• ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung CancersTerminatedNCT05616624Phase 1/2
• Surgery Versus Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung CancerActive, not recruitingNCT05183932
• Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLCWithdrawnNCT05007769Phase 2
• Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung CancerActive, not recruitingNCT04791839Phase 2
• Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT04743505Phase 1/2
• Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung CancerWithdrawnNCT03166254Phase 1
• Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)WithdrawnNCT02705339Phase 2
• SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung CancerCompletedNCT02562027Not applicable
• Genomic Landscape of CeritinibTerminatedNCT02554591
• Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid TumorsWithdrawnNCT02537561Phase 1
• Afatinib Genomic LandscapeTerminatedNCT02491775
• Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease ProgressionTerminatedNCT02431169
• Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC)WithdrawnNCT02419170Early Phase 1
• Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)TerminatedNCT02342353Phase 1
• Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung CancerCompletedNCT02172846Phase 1
• 64CuATSM and Hypoxia in Stage IV Non-small Cell Lung Cancer With Carboplatin, Paclitaxel, and BevacizumabWithdrawnNCT01006226Not applicable
• Temsirolimus and Radiation for Non-Small Cell Lung CancerCompletedNCT00796796Phase 1
• A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00555256Phase 1